Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02607319
Other study ID # AmericanUBMCRIF
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 2015
Est. completion date July 2022

Study information

Verified date July 2023
Source American University of Beirut Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the effect of Bemiparin, a low molecular weight heparin, on implantation rate in women with unexplained recurrent implantation failure undergoing IVF/ICSI treatment.


Description:

Recurrent implantation failure (RIF), defined as failure of conception following three or more consecutive In Vitro Fertilization (IVF) cycles despite the transfer of good quality embryos, is a major cause of distress amongst infertile couples. While factors underlying implantation failure are many, most cases remain unexplained. In order to improve pregnancy outcomes and delivery rates in women with unexplained RIF, various investigational treatments have been proposed. The investigators propose a prospective controlled randomized comparative study to evaluate the effect of Bemiparin on implantation rates in women with unexplained RIF. A total of 200 patients will be recruited and randomized between two groups. The study group will receive Bemiparin plus standard care; while the control group will receive only standard care. Treatment will start on the day following embryo transfer and will be continued until 12 weeks gestation in the event of pregnancy. The primary objective is to determine the effect of Bemiparin on implantation rate in women with unexplained recurrent implantation failure.


Recruitment information / eligibility

Status Completed
Enrollment 165
Est. completion date July 2022
Est. primary completion date July 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 38 Years
Eligibility Inclusion Criteria: - History of three or more consecutively failed In Vitro Fertilization (IVF) cycles after embryo transfer. - Normal uterine cavity (as assessed by hysteroscopy or HSG). - Normal hormonal investigation: TSH, PRL, FBS. - Normal acquired/inherited thrombophilia profile: LAC, ACA IgG/IgM, Prot S, Antithrombin III, beta-2 glycoprotein, Factors V, II, MTHFR. - Normal semen analysis and mild/moderate male factor (Total motile sperm count > 5 million/ml and/or normal WHO morphology >20%. - Patient provides written informed consent. Exclusion Criteria: - Evidence of low ovarian reserve by at least one of the following: AMH = 1,5 ng/mL and/or basal CD 3 FSH = 10 mIU/mL and/or basal CD 3 Estradiol = 60 ng/mL and/or previous egg collection yield = 3 oocytes. - Preexisting medical condition (thyroid disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac condition…). - Severe male factor infertility (Total motile sperm count < 5 million/ml and/or normal WHO morphology <20%). - Hypersensitivity to Heparin or its derivatives. - Acquired thrombophilia. - Active hemorrhage or increased risk of bleeding due to impairment of homeostasis. - Severe impairment of liver or pancreatic function. - Severe renal insufficiency (Creatinine Clearance < 30 ml/min). - Injuries to or operations on the central nervous system, eyes and ears within the last 2 months. - Disseminated Intravascular Coagulation (DIC) attributable to heparin-induced thrombocytopenia. - Acute bacterial endocarditis and endocarditis lenta. - Any organic lesion with high risk of bleeding (e.g.: active peptic ulcer, hemorrhagic stroke, cerebral aneurysm or cerebral neoplasms).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bemiparin sodium
Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.

Locations

Country Name City State
Lebanon American University of Beirut Medical Center Beirut

Sponsors (1)

Lead Sponsor Collaborator
American University of Beirut Medical Center

Country where clinical trial is conducted

Lebanon, 

Outcome

Type Measure Description Time frame Safety issue
Primary Implantation rate (%) Number of intrauterine gestational sacs observed by transvaginal ultrasonography divided by the number of transferred embryos Vaginal ultrasound at 8 weeks gestation
Secondary Live birth rate (%) birth of live born Time of delivery up to 42 weeks gestation
Secondary Ongoing pregnancy rate (%) Fetal heart beat seen by ultrasound at 20 weeks gestation Vaginal ultrasound at 20 weeks of gestation
Secondary Clinical pregnancy rate (%) Fetal heart beat seen by ultrasound at 8 weeks gestation Vaginal ultrasound at 8 weeks gestation
Secondary Total pregnancy rate (%) Positive hCG titer Up to 15 days from oocyte collection
See also
  Status Clinical Trial Phase
Completed NCT01955356 - Embryo Implantation After Induced Endometrial Injury N/A
Completed NCT01330784 - Assessment of the Therapeutic Utility of hMG-HP N/A
Completed NCT01330771 - Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP N/A
Active, not recruiting NCT05079685 - HyFoSy Versus HSG as a Diagnostic Technique for Tubal Patency.
Completed NCT04605003 - Effectiveness of Nasal Endoscope Sterilization Using a Novel Rig-S™ Device N/A
Completed NCT01331720 - Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation N/A
Completed NCT01331733 - Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist N/A
Not yet recruiting NCT02648555 - A Lifestyle Intervention to Improve in Vitro Fertilization Results N/A
Suspended NCT00749853 - Efficacy of Ovarian Stimulation Based on FSHR Genotype Status Phase 3
Recruiting NCT03177122 - Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology Phase 4
Completed NCT03169166 - The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies Phase 4
Completed NCT01406964 - Chlamidia Antibodies Test for Tubal Factor Screening N/A
Completed NCT01430650 - Endometrial Priming for Embryo Transfer Phase 4
Completed NCT03173404 - Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection N/A
Completed NCT03561129 - Embryotransfer Operator and Pregnancy Rate
Recruiting NCT05173597 - Real-world Evidence on Follitropin Delta Individual Dosing
Recruiting NCT04026282 - To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment N/A
Completed NCT03619707 - Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles Phase 4